ISSN: 1859 - 2872
Clinical characteristics of HER2-positive breast cancer molecular subtypes
Main Article Content
Keywords
Breast cancer, HER2 positive, molecular subtypes
Abstract
Summary
Objective: To observe some relations between clinical features and HER2 (+) breast cancer molecular subtypes. Subject and method: 153 HER2 (+) breast cancer patients were classified as subtypes by IHC stain and evaluating relations to clinical features. Result: HER2 subtypes often shows the poor clinical factors in high evidences such as large tumor size (more 5cm: 6.1%), up to 3 positive nodes (22.3%), high-risk group (22.2%) or stage III (27.3%). Conclusion: HER2 subtype is often associated in worse clinical factors than LUMA-HER2 hybrid and LUMB-HER2 hybrid subtypes.
Keywords: Breast cancer, HER2 positive, molecular subtypes
Article Details
References
1. Đoàn Thị Phương Thảo (2012) Nghiên cứu gen HER2 và phân nhóm phân tử ung thư vú. Luận án Tiến sĩ Y học, Trường Đại học Y Dược thành phố Hồ Chí Minh.
2. Adly S, Hewedi IH, Mokhtar NM (2010) Clinicopathologic significance of molecular classification of breast cancer: Relation to Nottingham prognosis index. Journal of the Egyptian Nat. Cancer Inst 22(4): 276-283.
3. Bhargava R, Beriwal S, Dabb DJ et al (2010) Immunohistochemical surrogate markers of breast cancer molecular classes predict response to neoadjuvant chemotherapy: A single Institutional experience with 359 cases. Cancer, in press: 357-363.
4. Carey LA, Perou CM, Livasy CA et al (2006) Race, breast cancer subtypes, and survival in the Carolina breast cancer study. JAMA 295(21): 2492-2502.
5. Cheang MC, Voduc D, Bajdik C et al (2008) Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14: 1368-1376.
6. Engstrøm MJ, Opdahl S, Hagen AI (2013) Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients. Breast Cancer Res Treat 140: 463-473.
7. Goldhirsch, A, Glick JH, Gelber RD et al (2005) Meeting highlights: International expert consensus on the primary therapy of early breast cancer. Ann Oncol 16: 1569-1583.
8. Perou CM, Sørlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature, 406(6797): 747-752.
9. Sorlie, T, Tibshirani R, Parker J et al (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100(14): 8418-8423.
10. Spitale, A, Mazzola P, Soldini D et al (2009) Breast cancer classification according to immunohistochemical markers: Clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland. Annals of Oncology 20: 628-635.
2. Adly S, Hewedi IH, Mokhtar NM (2010) Clinicopathologic significance of molecular classification of breast cancer: Relation to Nottingham prognosis index. Journal of the Egyptian Nat. Cancer Inst 22(4): 276-283.
3. Bhargava R, Beriwal S, Dabb DJ et al (2010) Immunohistochemical surrogate markers of breast cancer molecular classes predict response to neoadjuvant chemotherapy: A single Institutional experience with 359 cases. Cancer, in press: 357-363.
4. Carey LA, Perou CM, Livasy CA et al (2006) Race, breast cancer subtypes, and survival in the Carolina breast cancer study. JAMA 295(21): 2492-2502.
5. Cheang MC, Voduc D, Bajdik C et al (2008) Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14: 1368-1376.
6. Engstrøm MJ, Opdahl S, Hagen AI (2013) Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients. Breast Cancer Res Treat 140: 463-473.
7. Goldhirsch, A, Glick JH, Gelber RD et al (2005) Meeting highlights: International expert consensus on the primary therapy of early breast cancer. Ann Oncol 16: 1569-1583.
8. Perou CM, Sørlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature, 406(6797): 747-752.
9. Sorlie, T, Tibshirani R, Parker J et al (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100(14): 8418-8423.
10. Spitale, A, Mazzola P, Soldini D et al (2009) Breast cancer classification according to immunohistochemical markers: Clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland. Annals of Oncology 20: 628-635.
Article Sidebar
How to Cite
Tiến QuangN., & Văn ChủN. (2020). Clinical characteristics of HER2-positive breast cancer molecular subtypes. Tạp Chí Y Dược lâm sàng 108, 15(3). Retrieved from https://tcydls108.benhvien108.vn/index.php/YDLS/article/view/427